Tag: Mucosal leishmaniasis

With an estimated 350 million people worldwide at risk, leishmaniasis is a serious parasitic disease that can manifest in various forms. The development of effective oral treatments, such as the Impavido treatment (miltefosine), has significantly improved patient care for this often-neglected tropical disease.

With an estimated 0.7 to 1 million new cases annually, leishmaniasis is a significant global health issue. So, what does Impavido treat? This oral medication is a primary weapon against specific parasitic infections caused by the *Leishmania* parasite and is also used for other rare but deadly infections.